### **COUNTRY DATA**

EPIDEMIC ESTIMATES			
	2010	2015	2019
New HIV infections			
New HIV infections (all ages)	2600	3100	3300
	[2300–2800]	[2700–3500]	[2800–4000]
New HIV infections (0–14)	500	<500	<500
	[<500–610]	[<500–560]	[<500– <500]
New HIV infections (women, 15+)	1200	1500	1700
	[1000–1300]	[1300–1700]	[1400–2000]
New HIV infections (men, 15+)	890	1100	1300
	[760–1100]	[970–1400]	[1100–1700]
HIV incidence per 1000 population	0.35 [0.32–0.4]	0.39 [0.34–0.44]	0.38 [0.32–0.46]
AIDS-related deaths			
AIDS-related deaths (all ages)	770	640	610
	[610–940]	[530–780]	[500–750]
AIDS-related deaths (0-14)	<500	<500	<500
	[<500– <500]	[<200– <500]	[<200–<500]
AIDS-related deaths (women, 15+)	<500	<200	<500
	[<500– <500]	[<200– <500]	[<200–<500]
AIDS-related deaths (men, 15+)	<500	<200	<200
	[<200– <500]	[<200– <500]	[<200–<500]
People living with HIV			
People living with HIV (all ages)	33 000	42 000	52 000
	[30 000–37 000]	[38 000–47 000]	[47 000–57 000]
People living with HIV (0-14)	2600	3200	3200
	[2200–3000]	[2500–3700]	[2400–3800]
People living with HIV (women, 15+)	17 000	22 000	28 000
	[16 000–20 000]	[20 000–25 000]	[25 000–31 000]
People living with HIV (men, 15+)	13 000	17 000	21 000
	[12 000–15 000]	[15 000–19 000]	[19 000–23 000]
HIV prevalence (15–49)	0.7 [0.6–0.8]	0.8 [0.7–0.9]	0.9 [0.7–1]

			$\neg \cap \Box$	$\sim$ 1	-
$\mathbf{I} \cdot \mathbf{\Lambda} \mathbf{M}$	$\sim \Lambda N$		וווא		- V
	'S AN	$\boldsymbol{\mathcal{L}}$		VI.	டு

L WYS / WYD I OLIOILS	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, penalty not specified
Drug use or possession for personal use is an offence	Possession of drugs for personal use or drug use and/or consumption are specified as criminal offences
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	Yes

# STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49 years who report discriminatory attitudes towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

# VIOLENCE

Proportion of ever-married or partnered
women aged 15-49 years who experienced
physical or sexual violence from a male
intimate partner in the past 12 months
intimate partner in the past 12 months

2018

47.6


$\Gamma V$	DEN	171	ID	-


residence permits or for certain groups


H	EXPENDITURES							
Financing sources								
		Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total	


Last available report: 2012 US\$ 740 081 US\$ 6 385 677 US\$ 1 577 356 US\$ 27 388 589 US\$ 36 659 267

## EPIDEMIC TRANSITION METRICS









Change in new 30% **HIV** infections since 2010

Change in AIDSrelated deaths since 2010

-20%

Incidence: 6.43 prevalence ratio

Incidence: mortality ratio\*


<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATION	1S				
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	48 000	36 000			
HIV prevalence	15.5%	7.7%			
HIV testing and status awareness		59.0%			
Antiretroviral therapy coverage					
Condom use	31.7%				
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

Estimated number of incident tuberculosis cases among people living with HIV (2018)	2700 [2200 –3300]
People living with HIV who started TB preventive therapy (2018)	20.7%
Cervical cancer screening of women living with HIV	
D	

HIV COMORBIDITIES

## HIV TESTING AND TREATMENT CASCADE



5 000				0%
-	People living with HIV who know their status	People living with HIV on treatment	People living with HIV who are virally suppressed	0 76
All ages	71% [64–78%]	62% [56–68%] 32 018	% [%]	
Children (0-14	49% [37–58%]	49% [37–58%] 1 544	% [–%]	
Women (15+)	76% [69–84%]	67% [61–75%] 18 717	% [%]	
Men (15+)	67% [60–75%]	57% [51–63%] 11 757	% [%]	

preventive therapy (2018)	20.7%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	
HIV PREVENTION	

### HIV PREVENTION Adults aged 15+ years with unsuppressed viral load Knowledge of HIV prevention among young people aged 15-24 years (2017) — Women 24.4% — Men 26.2% Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years (2018) — Women 18% — Men 33.2% Women aged 15-49 years who have their demand for family planning satisfied by 49.2% modern methods (2018) Not Men aged 15-49 years who are circumcised applicable Voluntary medical male circumcisions Not performed according to national standards applicable People who received PrEP at least once during the reporting period Harm reduction

	2010	2019
Percentage of pregnant women living with HIV	5%	81%
accessing antiretroviral medicines	[4–7%]	[60–100%]
Final vertical transmission rate including during	39%	23%
breastfeeding	[36–42%]	[20–26%]
Early infant diagnosis	%	67.8%
Early Illiant diagnosis	[%]	[55.4-91.3%]

— Use of sterile injecting equipment at	
last injection	

- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy

No

No

- Naloxone available (2019)
- Safe injection rooms available (2019)